Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein naked cuticle homolog 1 (NKD1) is a member of the Naked cuticle (Nkd) family and functions as a cytoplasmic antagonist of the canonical Wnt signaling pathway[1][3][4]. NKD1 contains an EF-hand calcium-binding motif, is membrane-associated (via N-terminal myristoylation), and primarily inhibits Wnt/β-catenin signaling by binding Dishevelled (Dvl) family proteins, leading to their destabilization[1][3][5]. Loss or mutation of NKD1 disrupts this inhibition, resulting in β-catenin stabilization and increased cell proliferation[3]. Mutations in NKD1 have been identified in a subset of DNA mismatch repair-deficient colorectal cancers, implicating NKD1 in the negative regulation of the Wnt pathway during tumorigenesis[1][3]. As a feedback inhibitor, NKD1 ensures proper modulation of Wnt signal strength and duration; defects in its function are associated with increased cancer risk, especially when other classic Wnt regulators are not mutated[1][3]. Current evidence supports its biological and disease relevance, but there are no known direct therapeutic drugs targeting NKD1 itself.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein naked cuticle homolog 1 (NKD1).